erbBGenes in the Mouse Uterus: Cell-Specific Signaling by Epidermal Growth Factor (EGF) Family of Growth Factors during Implantation  by Lim, Hyunjung et al.
erbB Genes in the Mouse Uterus: Cell-Specific
Signaling by Epidermal Growth Factor (EGF) Family
of Growth Factors during Implantation
Hyunjung Lim, Sanjoy K. Das,1 and Sudhansu K. Dey1
Department of Molecular and Integrative Physiology, Ralph L. Smith Research Center,
University of Kansas Medical Center, Kansas City, Kansas 66160-7338
We previously described spatiotemporal expression of various epidermal growth factor (EGF)-like ligands and receptor
subtypes, ErbB1 and ErbB2, during the peri-implantation period. To better understand the roles of these ligands and their
possible signaling schemes in implantation, it is important to define the status of all the ligands and receptor subtypes in
the uterus/embryo. No information is available about uterine and embryonic status of ErbB3 or ErbB4 during implantation.
We cloned mouse erbB3 and erbB4 cDNAs and examined their expression and bioactivity in the peri-implantation uterus
(days 1–8). Two erbB3 (cytoplasmic and extracellular) and three erbB4 (two cytoplasmic and one extracellular) clones were
generated. Both forms of the erbB3 clone showed similar transcript profiles, while different transcript profiles were obtained
with erbB4 clones. The steady-state levels of erbB3 and erbB4 mRNAs in whole uterine poly(A)1 RNA samples showed
little changes during the peri-implantation period, while their unique cell-specific accumulation was noted. erbB3 is
predominantly expressed in the epithelial cells, although decidual and embryonic cells also accumulate this mRNA. In
contrast, the erbB4 mRNA is primarily expressed in the submyometrial stroma and myometrial connective tissues during
this period. Additionally, the extracellular form of the erbB4 clone detected signals in a subpopulation of stromal cells.
Autophosphorylation and immunoprecipitation studies provided evidence that uterine ErbB3 and ErbB4 are biologically
active. This study provides a comprehensive analysis of possible ligand–receptor signaling schemes for EGF-like ligands in
implantation. © 1998 Academic Press
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INTRODUCTION
Synchronized development of the embryo to the blastocyst
stage and preparation of the uterus to the receptive state are
essential for successful implantation (Psychoyos, 1973; Paria
et al., 1993b). The establishment of the receptive uterus is
achieved by the coordinated effects of progesterone (P4) and
estrogen in a temporal and cell type-specific manner (Huet-
Hudson et al., 1989). In the mouse, the uterine epithelium on
days 1 and 2 of pregnancy undergoes proliferation under the
influence of preovulatory estrogen. In contrast, increasing
levels of P4 from the newly formed corpora lutea on day 3
result in the switching of proliferation from the epithelium to
the stroma which is further potentiated by preimplantation
ovarian estrogen secretion on day 4. The uterine receptivity is
achieved on day 4 when epithelial cells cease to proliferate and
become differentiated (Huet-Hudson et al., 1989). The attach-
ment reaction occurs at 2200–2300 h on this day and is
followed by penetration by trophoblast cells through the
underlying basement membrane. This is accompanied by
transformation of stromal cells into decidual cells (decidual-
ization) (Dey, 1996). Although the molecular mechanism(s)
that directs steroid hormone-mediated proliferation/differen-
tiation of uterine cells for implantation and decidualization is
poorly defined, the regulated expression of polypeptide growth
factors and their receptors in the uterus and embryo during the
peri-implantation period or under steroid hormonal stimula-
tion suggests that these factors serve as local mediators of
steroid hormone actions (Das et al., 1992, 1994a,b, 1995, 1997;
Huet-Hudson et al., 1990; Kapur et al., 1992; Lim et al., 1997;
Murphy et al., 1987; Paria et al., 1992, 1993a, 1994; Paria and
Dey, 1990; Rappollee et al., 1988; Tamada et al., 1991).
Our laboratory has been engaged in defining the roles of
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the EGF family of growth factors in uterine biology and
implantation. The members of the EGF family are EGF
itself, transforming growth factor-a (TGF-a), amphiregulin
(Ar), heparin-binding EGF-like growth factor (HB-EGF), be-
tacellulin, epiregulin, and neuregulins 1–3 (NRGs) (Cohen,
1962; Derynck et al., 1984; Shoyab et al., 1988; Higash-
iyama et al., 1991; Holmes et al., 1992; Shing et al., 1993;
Toyoda et al., 1995; Chang et al., 1997; Carraway et al.,
1997; Zhang et al., 1997). These ligands can interact with
the receptor subtypes of the erbB gene family which is
composed of four receptor tyrosine kinases: ErbB1 (EGF-
receptor), ErbB2, ErbB3, and ErbB4. They share a common
structural feature, but differ in their ligand specificity and
kinase activity (Carraway and Cantley, 1994; Heldin, 1995;
Lemke, 1996). While EGF, TGF-a, HB-EGF, Ar, betacellu-
lin, and epiregulin all can directly bind to ErbB1, all NRGs
require either ErbB3 and/or ErbB4 for direct binding (Tzahar
et al., 1994; Riese et al., 1996; Komurasaki et al., 1997;
Carraway et al., 1997; Chang et al., 1997; Zhang et al.,
1997). Additionally, betacellulin, HB-EGF, and epiregulin
can serve as direct ligands for ErbB4 (Riese et al., 1996,
1998; Elenius et al., 1997a; Komurasaki et al., 1997; Shelly
et al., 1998). Epiregulin is unique since it can interact with
many different combinations of heterodimers with low
affinity (Shelly et al., 1998). Although there is no ligand
known to interact directly with ErbB2, this receptor pos-
sesses the strongest kinase activity and is considered as the
preferred partner in forming dimers with other members of
the family (Karunagaran et al., 1996; Graus-porta et al.,
1997). In contrast, ErbB3 exhibits impaired kinase activity
and requires heterodimerization with other receptor sub-
types for intracellular signaling (Guy et al., 1994; Chen et
al., 1996). The initial dimerization between the coexpressed
receptors upon specific ligand binding constitutes the clas-
sical mechanism of actions of EGF-like ligands. However,
the incidence of the “secondary dimerization” after recep-
tor dissociation suggests that the receptor activation is not
necessarily correlated with direct ligand binding (Gamett et
al., 1997). Furthermore, coexpression of ErbB2 and ErbB3 in
an engineered cell line creates previously undescribed bind-
ing sites for EGF and betacellulin (Alimandi et al., 1997;
Pinkas-Kramarski et al., 1998). These observations suggest
extensive “cross-talk” among the receptor subtypes involv-
ing various mechanisms. Therefore, depicting the expres-
sion patterns of the EGF and ErbB family members in the
peri-implantation uterus with changing cellular phenotypes
is important in defining their possible ligand–receptor sig-
naling network during this period.
We have previously examined the expression and regula-
tion of EGF, TGF-a, Ar, HB-EGF, betacellulin, epiregulin,
and NRG1 in the mouse uterus during the peri-
implantation period (Huet-Hudson et al., 1990; Tamada et
al., 1991; Das et al., 1994b, 1995, 1997; Reese et al., 1998).
Collectively, the results suggest that Ar may be involved in
uterine preparation for implantation, while HB-EGF could
interact with blastocyst ErbB1/EGF-R for the attachment
reaction (Das et al., 1994b; Raab et al., 1996). Further,
overlapping uterine cell-specific expression of Ar, HB-EGF,
betacellulin, epiregulin, and NRG1 surrounding the im-
planting blastocyst suggests that these growth factors are
important for the attachment reaction (reviewed in Das et
al., 1997). However, distinct spatiotemporal expression of
these growth factors in the pre- and postimplantation
uterus also suggests that they serve specific functions
associated with uterine preparation for implantation. These
studies also suggested that steroid hormonal regulation of
uterine cell proliferation and differentiation is mediated
locally by these growth factors. With respect to ErbB
receptors, ErbB1 and ErbB2 are expressed in a spatiotempo-
ral manner in the peri-implantation uterus and show ste-
roid hormone responsiveness (Das et al., 1994a; Lim et al.,
1997). In the present investigation, we examined whether
ErbB3 and ErbB4 can also serve as potential mediators for
EGF-like growth factors in implantation. We cloned the
mouse erbB3 and erbB4 cDNAs to examine their spatio-
temporal expression and their bioactivity in response to
various ligands in the peri-implantation uterus. We identi-
fied two species of the erbB4 mRNA spliced transcripts in
the cytoplasmic region which exhibited differential expres-
sion in the uterus. These observations coupled with our
previous results (Das et al., 1994a; Lim et al., 1997) depict
for the first time the potential compartmentalized signaling
by EGF-like growth factors in a complex in vivo system.
MATERIALS AND METHODS
Growth Factors and Antibodies
Receptor-grade mouse EGF was purchased from Upstate Biotech-
nology, Inc. (Lake Placid, NY), while recombinant human betacel-
lulin and amphiregulin were procured from R & D Systems
(Minneapolis, MN). Human recombinant HB-EGF and NRG1b
were kindly provided by Dr. Judith Abraham (Scios Nova Inc.,
Mountain View, CA) and Dr. K. Carraway, III (Harvard Medical
School, Boston, MA), respectively. Mouse epiregulin was provided
by Dr. T. Komurasaki (Taisho Pharmaceutical Co., Japan). The
rabbit polyclonal antibodies to mouse ErbB3 and ErbB4 were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA) and
these antibodies do not show cross-reactivity with other ErbB
members.
Animals and Tissue Preparation
CD-1 mice (Charles River Laboratory, Raleigh, NC) were housed
in the animal care facility at the University of Kansas Medical
Center according to NIH and institutional guidelines for the care of
laboratory animals. Adult female mice (20–25 g, 48–60 days old)
were mated with fertile males of the same strain. The morning of
finding a vaginal plug was designated day 1 of pregnancy. Mice
were killed between 0830 and 0900 h on days 1–8 of pregnancy.
Embryos were recovered from the reproductive tract on days 1–4 to
confirm pregnancy. Implantation sites on days 5 and 6 were
visualized by intravenous injection (0.1 ml/mouse) of Chicago blue
dye solution (0.1% in saline). Implantation sites were demarcated
by discrete blue bands along the uterus (Paria et al., 1993b). On days
7–8, implantation sites are distinct and blue dye injection is not
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required. Uteri were collected for Northern blot hybridization, in
situ hybridization, or autophosphorylation studies.
Cloning and Sequencing of the Mouse erbB3 and
erbB4 Partial cDNAs
Reverse-transcription polymerase chain reaction (RT-PCR) was
employed to generate the mouse-specific erbB3 and erbB4 cDNA
clones. RT-PCR conditions were essentially the same as described
previously (Paria et al., 1993a). Two sets of primers (sense and
antisense), based on the human cDNA sequence, were used to
generate the mouse erbB3 cDNAs. The first set of primers, 59-
GATGCTGAGAACCAATACCAGACAC-39 (sense) and 59-
CAATATAAACACCCCCTGACAGAATC-39 (antisense), were
used to generate partial cDNA clones of the extracellular domain in
the mouse erbB3 gene (erbB3E). The sense strand primer corre-
sponds to 220–244 nt, whereas the antisense strand primer encom-
passes 522–547 nt in the human erbB3 gene. The second set of
primers, 59-TCTGGATACATGCCCATGAACCAGGGTAATCT-
TGG-39 (sense) and 59-CCTTTGAGGTGTGTATCTGGCAT-
GACATAACC-39 (antisense), were used to generate partial cDNA
clones of the cytoplasmic domain in the mouse erbB3 gene
(erbB3C) (Moscoso et al., 1995). These primers encompass 3253–
3287 and 3571–3602 nt of the human erbB3 gene, respectively.
Partial cDNA clones of the extracellular domain in the mouse
erbB4 gene (erbB4E) were generated by using 59-CAGAAA-
ATCATTGCCAGACTTTGAC-39 (sense) and 59-CACGCACACA-
AGAACTGGAATCTAC-39 (antisense) primers, which encompass
635–659 and 928–952 nt in the human sequence (Plowman et al.,
1993). Mouse-specific primers 59-GCTGAGGAATATTTGGT-
CCC-39 (sense) and 59-CTACTGGAGCCTCTGGTATG-39 (anti-
sense) were designed to clone the cytoplasmic domain of the erbB4
(erbB4C) (Moscoso et al., 1995). Day 4 pregnant mouse uterine total
RNA (1 mg) was reverse transcribed using each antisense primer as
indicated above. RT products (3 ml) were amplified by PCR for 45
cycles using the following cycle parameters: 94°C, 1 min 30 s;
55°C, 2 min; 72°C, 2 min 30 s. The RT-PCR products were
analyzed by Southern hybridization using a 32P end-labeled internal
primer designed from the human erbB3 or erbB4 sequence. RT-
PCR products were cloned into pCR-Script SK(1) cloning vector
(Stratagene, La Jolla, CA) and nucleotide sequences of the clones
were determined on both strands by dideoxy nucleotide chain
termination method (Sanger et al., 1977) and the Sequenase version
2.0 kit (United States Biochemical, Cleveland, OH).
Hybridization Probes
Antisense 32P-labeled cRNA probes for Northern hybridization
and 35S-labeled cRNA probes (sense and antisense) for in situ
hybridization were generated from cDNAs of the mouse erbB1,
erbB2, erbB3E, erbB3C, erbB4E, erbB4C/L, erbB4C/S, and rpL7
using appropriate polymerases (Das et al., 1994a; Lim et al., 1997;
Lim and Dey, 1997). For Southern hybridization, specific internal
primers were end-labeled with [g-32P]ATP using T4 polynucleotide
kinase. Probes had specific activities of about 2 3 109 dpm/mg.
Northern Blot Hybridization
Total RNAs of whole uteri pooled from 10–15 mice on indicated
days of pregnancy were extracted by a modified guanidine thiocya-
nate procedure (Das et al., 1994a,b). Poly(A)1 RNAs were isolated
from total RNAs by oligo(dT)–cellulose column chromatography
(Sambrook et al., 1989). Poly(A)1 RNA (2 mg) was denatured,
separated by formaldehyde–agarose gel electrophoresis, transferred
to nylon membranes, and cross-linked by UV irradiation (Spec-
trolinker XL-1500, Spectronics Corp., Westbury, NY). The blots
were prehybridized, hybridized, and washed as described previ-
ously (Das et al., 1994a). After hybridization, the blots were washed
under stringent conditions and the hybrids were detected by
autoradiography. The blots were stripped and rehybridized with
ribosomal protein L7 (rpL7) probe as described previously (Lim and
Dey, 1997).
In Situ Hybridization
In situ hybridization was performed as described previously (Das
et al., 1994b). Uteri were cut into 4- to 6-mm pieces and flash
frozen in Histo-Freeze (Fisher Scientific, St. Louis, MO). Frozen
sections (11 mm) from days 1, 4, 5, and 8 or days 2, 3, 6, and 7 of
pregnancy were mounted onto poly-L-lysine-coated slides and fixed
in cold 4% paraformaldehyde in PBS. The sections were acetylated
and hybridized at 45°C for 4 h in 50% formamide hybridization
buffer containing the 35S-labeled antisense cRNA probe. After
hybridization and washing, the sections were incubated with
RNase A (20 mg/ml) at 37°C for 20 min. RNase A-resistant hybrids
were detected by autoradiography using Kodak NTB-2 liquid emul-
sion (Eastman Kodak, Rochester, NY). Sections hybridized with the
corresponding sense probe served as negative controls. Slides were
poststained with hematoxylin and eosin.
Autophosphorylation of Uterine ErbB3 and ErbB4
The method essentially followed the protocol described by us
previously (Das et al., 1994a). In brief, day 4 pregnant uteri were
homogenized in buffer A [10 mM Tris–HCl (pH 7.5), 250 mM
sucrose, 2 mM EGTA, 10 mg/ml leupeptin, 20mg/ml PMSF, 10
mg/ml aprotinin] and centrifuged at 900g for 10 min at 4°C. The
supernatant was centrifuged at 144,000g for 1 h at 4°C. The pellet
was resuspended in the same buffer and subjected to similar
centrifugation for another hour. The pellet was resuspended in
buffer B [10 mM Tris–HCl (pH 7.4), 0.15 mM NaCl, 1 mM EGTA,
10 mg/ml leupeptin, 20 mg/ml PMSF, 10 mg/ml aprotinin]. Mem-
branes (150 mg protein) were suspended in 50 ml phosphorylation
reaction buffer [50 mM Pipes (pH 7.0), 1 mM MnCl2, 0.1 mM
Na–vanadate] and preincubated with or without a specific ligand
(100 ng/ml) for 10 min at 4°C. The labeling reaction was performed
for 2 min at 4°C after addition of 5 mCi [g-32P]ATP (1 mM) in the
presence of 0.1% Triton X-100. The reaction was terminated by 15
ml of an ice-cold mixture of 1 mM ATP and 0.1% BSA followed by
an equal volume (w/v) of 10% trichloroacetic acid. After incubation
on ice for 1 h, the mixture was centrifuged. The precipitates were
washed three times with a mixture of diethylether and ethanol (1:1)
and suspended in 50 ml of 50 mM Tris buffer (pH 7.5). An equal
volume of protein A/Sepharose–antibody conjugate (3 mg:0.5 mg)
was added to this mixture and incubated for 90 min at 4°C with
constant shaking. The protein A/Sepharose–antibody conjugates
were washed sequentially with buffer A (50 mM Hepes, 0.1%
Triton X-100, 0.1% SDS, 5 mM EGTA, pH 8.0), buffer B (50 mM
Hepes, 0.1% Triton X-100, 0.1% SDS, 150 mM NaCl, pH 8.0), and
buffer C (10 mM Tris–HCl, pH 8.0). The pellets were boiled in 13
SDS sample buffer (62.5 mM Tris, pH 6.8, 2% SDS, 10% glycerol,
5% b-mercaptoethanol) for 3 min and centrifuged. The superna-
tants were subjected to 7.5% SDS–PAGE in parallel with molecular
weight markers. The gel was transferred to nitrocellulose mem-
brane and the products were visualized by autoradiography.
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FIG. 1. Partial nucleotide and amino acid sequences of the mouse erbB3 and erbB4 cDNAs. Nucleotide sequences of the mouse erbB3 and
erbB4 partial cDNA clones isolated by RT-PCR are shown. The deduced amino acid sequence is shown by one-letter amino acid code.
Differences in amino acid residues in the mouse sequences with those in the human are indicated. (A) erbB3E; (B) erbB4E; (C) erbBC/L.
Amino acid residues that are present only in the erbB4C/L are shown in bold characters. The sequence data for erbB3E, erbB4E, and
erbB4C/L are available from GenBank/EMBL/DDBJ under Accession Nos. AF059175, AF059176, and AF059177, respectively.
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RESULTS
Mouse erbB3 and erbB4 cDNA Sequences
The partial clone of the extracellular domain in the
mouse erbB3 cDNA (erbB3E) is 277 bp encompassing
245–521 nt (codons 49–141) of the human erbB3 cDNA
(Kraus et al., 1989) (Fig. 1). This region shows 87 and 92%
nucleic acid sequence homologies to the human and rat
erbB3, while the deduced amino acid sequence is 97 and
98% homologous to human and rat ErbB3, respectively
(Kraus et al., 1989; Hellyer et al., 1995). As reported
previously (Moscoso et al., 1995), the partial clone of the
cytoplasmic domain in the mouse erbB3 cDNA (erbB3C) is
composed of 283 bp encompassing 3288–3570 nt (codons
1064–1157) of the human sequence. The cloned erbB4E
(extracellular domain) is 268 bp encompassing 660–927 nt
(codons 209–298) of the human erbB4. This region has 92%
nucleic acid sequence homology to the human erbB4 cDNA
with 99% amino acid sequence homology (Plowman et al.,
1993). The primers used to generate a partial clone of the
cytoplasmic domain in the erbB4 (erbB4C) produced two
different products. As reported previously (Moscoso et al.,
1995), a short form (erbB4C/S) of 178 bp was generated. In
addition, a 226-bp fragment (erbB4C/L) with in-frame in-
sertion of 48 nt was identified. This cDNA encompasses
3088–3313 nt in the human erbB4 sequence with 85%
nucleic acid and 88% amino acid sequence homologies
(Plowman et al., 1993). Although the significance of these
two erbB4C products is not clear, erbB4C/L and erbB4C/S
clearly exhibited differential expression patterns in several
mouse tissues examined by RT-PCR. For example, the
erbB4C/S was predominantly expressed over the erbB4C/L
in the brain, kidney, and heart (data not shown). In contrast,
primarily the erbB4C/L was detectable in pregnant mouse
uterine tissues, albeit at much lower levels than those in
the brain, kidney, or heart (data not shown).
Northern Blot Analysis of erbB3 and erbB4
mRNAs in the Peri-implantation Uterus
Each of the erbB3 and erbB4 clones was used to analyze
the steady-state levels of their mRNAs in the peri-
implantation mouse uterus (days 1–8). Both of the erbB3
clones (erbB3E and erbB3C) detected a single '5.5-kb
transcript. The erbB3 mRNA is expressed on all days of
pregnancy examined; data of the erbB3E are shown (Fig.
2A). Each of the three erbB4 clones showed distinct tran-
script profiles (Fig. 2B). The common transcripts detected
by these clones are '5.5, '4.0, and '2.5 kb (marked with
an asterisk). However, erbB4E also detected additional
transcripts of '10 kb (a) and '1.6 kb (b). Further, the
erbB4C/L clone detected '10-kb (a) and '1.4-kb (c) tran-
scripts, while the erbB4C/S clone detected '1.4-kb (c) and
'1.8-kb (d) transcripts. In general, these transcripts were
expressed in the mouse uterus without showing much
variation during the peri-implantation period. The signifi-
cance of multiple transcripts is not yet clearly understood.
In Situ Hybridization Analysis of erbB3 and erbB4
mRNAs in the Peri-implantation Uterus
The steady-state levels of the erbB3 and erbB4 mRNAs in
whole uterine RNA samples showed little changes. How-
ever, in situ hybridization exhibited unique cell-specific
FIG. 2. Northern blot analysis of erbB3 and erbB4 mRNAs in the
peri-implantation mouse uterus. The mRNA levels were detected
in poly(A)1 samples obtained from the whole uterus on days 1–8 of
pregnancy. Autoradiographic exposures were as follows: (A)
erbB3E, 7.5 h; (B) erbB4E, 16 h; erbB4C/L, 16 h; erbB4C/S, 2 days;
rpL7, 1 h. Three common transcripts (5.5, 4.0, and 2.5 kb) detected
by all three erbB4 clones are marked with an asterisk (*). Addi-
tional transcripts are erbB4E: (a) '10 kb, (b) '1.6 kb; erbB4C/L: (a)
'10 kb, (c) '1.4 kb; and erbB4C/S: (c) '1.4 kb, (d) '1.8 kb. These
experiments were repeated twice using independent RNA samples
with similar results.
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FIG. 3. In situ hybridization of the erbB3 mRNA in the peri-implantation mouse uterus. Uterine sections on days 1, 4, 5, and 8 or days
2, 3, 6, and 7 of pregnancy were mounted onto the same slide. Sections were hybridized with 35S-labeled antisense cRNA probes. RNase-A
resistant hybrids were detected by autoradiography after 7 days of exposure. Uterine erbB3 mRNA distribution on days 1 (a, b), 4 (c, d), 5
(e, f), 7 (g, h), and 8 (i, j) of pregnancy is shown in brightfield (left column) and darkfield (right column) photomicrographs at 403. le, luminal
epithelium; ge, glandular epithelium; s, stroma; myo, myometrium; bl, blastocyst; pdz, primary decidual zone; sdz, secondary decidual
zone; em, embryo; epc, ectoplacental cone; tgc, trophoblastic giant cells. These experiments were repeated three times using independent
samples with similar results.
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accumulation of these mRNAs in the peri-implantation
uterus. In the preimplantation and early postimplantation
uterus (days 1–5), the erbB3 mRNA was predominantly
localized in the luminal and glandular epithelial cells (Figs.
3a–3f). Epithelial cell accumulation of erbB3 mRNA was
retained on days 6 and 7. In addition, signals were present in
the secondary decidual zone (Figs. 3g and 3h). On day 8,
trophoblastic giant cells surrounding the embryo, ectopla-
cental cone, and the embryo exhibited strong signals for
erbB3 mRNA (Figs. 3i and 3j).
In contrast to the predominant epithelial accumulation of
the erbB3 mRNA, the erbB4 mRNA was primarily ex-
pressed in the submyometrial stroma and myometrial con-
nective tissues. The accumulation was low in other areas of
FIG. 4. In situ hybridization of the erbB4 mRNAs in the peri-implantation mouse uterus. (A) distribution of erbB4E mRNA. a, brain; b–e,
uterine sections from days 1, 4, 5, and 8 of pregnancy. (B) distribution of erbB4C/L (left column) and erbB4C/S (right column) mRNAs. a
and b, brain; c and d, day 4 uterus, e and f, day 8 uterus. Exposure times for A and B are 8 and 12 days, respectively. All photomicrographs
are shown in darkfield at 403. le, luminal epithelium; s, stroma; myo, myometrium; bl, blastocyst; pdz, primary decidual zone; sdz,
secondary decidual zone; em, embryo. These experiments were repeated three times using independent samples with similar results.
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the stroma and in epithelial cells. The erbB4E clone de-
tected abundant signals in the stroma, primarily in the
submyometrial region of the day 1 uterus (Fig. 4A, b). On
days 4 and 5, the distinct accumulation was again evident
in the myometrial connective tissues and submyometrial
stromal cells (Fig. 4A, c and d). In addition, a subpopulation
of cells dispersed in the stromal bed exhibited strong signals
(see arrowheads in Fig. 4A, c); the identities of these cells
are not clear. In contrast, stromal and myometrial accumu-
lation was downregulated on day 8, except with modest
expression in the secondary decidual zone and a subpopu-
lation of cells in the decidual bed. Accumulation of the
erbB4E mRNA was also distinct in the day 8 embryo (Fig.
4A, e). Interestingly, a clear distinction was noted when two
clones of cytoplasmic regions were used for in situ hybrid-
ization (Fig. 4B). The uterine expression pattern with the
erbB4C/L clone closely followed that of the erbB4E clone,
although the levels of signals in the subpopulation of
stromal cells were lower (Fig. 4B, c and e). The signals
detected by the erbB4C/S clone were very low in peri-
implantation uterine cells (Fig. 4B, d and f). Mouse brain
sections served as positive controls. As reported (Pinkas-
Kramarski et al., 1997), a subpopulation of neuronal cells
throughout the cortex exhibited accumulation of the erbB4
mRNA. All three clones showed similar expression pat-
terns in these cells (Fig. 4A, a; 4B, a and b). Sections
hybridized with sense probes did not exhibit any positive
signals (data not shown).
Phosphorylation of ErbB3 and ErbB4 in the Uterus
Employing immunoprecipitation with specific antibod-
ies, we examined bioactivities of ErbB3 and ErbB4 in
uterine membrane preparations in response to various EGF-
like ligands. Because various EGF-like ligands are expressed
from the time of implantation on day 4 night (Das et al.,
1997), day 4 morning uterine samples were used to avoid
possible desensitization of these receptors by in vivo expo-
sure to these ligands (Countaway et al., 1992). EGF, TGFa,
HB-EGF, epiregulin, NRG1b, and betacellulin were used in
our experiments. As shown in Fig. 5, phosphorylation of
ErbB3 was stimulated by EGF, TGFa, HB-EGF, and betacel-
lulin, while epiregulin and NRG1b were ineffective. Like-
wise, phosphorylation of ErbB4 occurred when membranes
were challenged with EGF, TGFa, HB-EGF, and betacellu-
lin. In addition, epiregulin induced phosphorylation of
ErbB4 as reported previously (Komurasaki et al., 1997; Riese
et al., 1998; Shelly et al., 1998), but to a lesser extent. Ar
was ineffective in phosphorylating uterine ErbB3 and
ErbB4, although this ligand induced phosphorylation of
uterine (Das et al., 1995) and liver ErbB1 in our control
experiments (data not shown). Although NRG1b is known
as a ligand for both ErbB3 and ErbB4, it showed very little
phosphorylation of these receptors under our experimental
conditions.
Composite Analysis of in Situ Hybridization of
erbBs in Day 5 Implantation Sites
An analysis of in situ localization of erbB1, erbB2, erbB3,
and erbB4 mRNAs at the implantation sites on day 5 of
pregnancy is shown (Fig. 6A). As reported previously (Das et
al., 1994; Tong et al., 1996), the full-length erbB1 mRNA is
expressed in the stroma surrounding the blastocyst, while
erbB2 is predominantly expressed in the epithelium irre-
spective of the location of blastocysts and to a lesser extent
in the stroma (Lim et al., 1997). The localization of erbB3
and erbB4E has already been described (Figs. 3e and 3f and
Fig. 4A, d). The proposed ligand–receptor signaling network
in the uterus during implantation is primarily based on this
analysis (Fig. 6B).
DISCUSSION
The EGF family of growth factors and their receptor
subtypes are being studied more extensively in cancer cells
because their overexpression or constitutive expression is
correlated with tumorigenesis (Slamon et al., 1989; Juhl et
FIG. 5. Phosphorylation of uterine ErbB3 and ErbB4 by EGF-like
ligands. Phosphorylation of ErbB3 or ErbB4 was determined in day
4 uterine membranes after preincubation with or without (control)
EGF, TGF-a, HB-EGF, epiregulin, NRG1b, or betacellulin (100
ng/ml). The labeling reaction was initiated by the addition of
[g-32P]ATP. After 2 min labeling, immunoprecipitations were per-
formed with antibodies that are specific to ErbB3 or ErbB4. Precipi-
tated proteins were separated by 7.5% SDS–PAGE, transferred to
nitrocellulose membrane, and detected by autoradiography for 5
and 10 h for ErbB3 and ErbB4, respectively. IP, immunoprecipita-
tion. These experiments were repeated three times using indepen-
dent membrane preparations with similar results.
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al., 1998). However, little is known regarding the roles of
these growth factors/receptors in normal cellular processes
due to lack of information about their spatiotemporal
expression and complex signaling pathways. We have pre-
viously observed that EGF-like ligands and their receptor
subtypes, ErbB1 and ErbB2, are expressed in the peri-
implantation uterus and embryo in a spatiotemporal man-
ner (Das et al., 1994, 1997; Lim et al., 1997). These obser-
vations coupled with our present results of ErbB3 and ErbB4
have enabled us to describe a comprehensive analysis and a
scheme for cellular sites of ligand–receptor availability and
signaling network during early pregnancy (Fig. 6B).
In this study, we have identified previously undescribed
isoforms of the mouse erbB4 mRNA spliced variants in the
cytoplasmic region (erbB4C/L and erbB4C/S). The
erbB4C/S is 48 nt shorter than the erbB4C/L which is
homologous to the human erbB4 (Plowman et al., 1993).
However, the significance of these forms in the mouse is
not yet clear. It is interesting to note that all three erbB4
clones exhibited distinct transcript profiles, localization,
and abundance in the uterus (Fig. 2B). This implies multiple
truncation of mouse ErbB4 involving both cytoplasmic and
extracellular regions. A recent work described two alterna-
tively spliced isoforms of the human erbB4 (HER4) gene
that differ at the juxtamembrane region with distinct cel-
lular functions (Elenius et al., 1997b). Likewise, an intra-
cellular truncated product of the human ErbB2 and various
alternate transcripts of the human erbB3 were isolated from
carcinoma cell lines, suggesting their implications in both
pathogenic and normal cellular processes (Scott et al., 1993;
Lee and Mailhe, 1998). The mechanisms by which these
uterine isoforms of the mouse erbB4 are generated and
whether they possess distinct and/or overlapping functions
require further investigation.
Our observation of predominant epithelial expression of
the erbB3 gene in the peri-implantation mouse uterus is
consistent with its expression in many human cell types of
epithelial origin (Kraus et al., 1989), suggesting its direct
involvement in epithelial cell proliferation and/or differen-
tiation (Fig. 3). However, the decidual expression of the
erbB3 mRNA on days 6 and 7 of pregnancy suggests its role
in stromal cell transformation into decidual cells. The
expression of erbB3 in the ectoplacental cone and subsets of
trophoblastic giant cells is similar to that of the erbB2 gene
(Lim et al., 1997). This coexpression suggests that signaling
through these receptors is involved in decidualization,
regulation of trophoblast invasion, and perhaps subsequent
placentation. Among the three erbB4 clones, erbB4E
showed the most abundant expression in the uterus. Fur-
ther, this clone detected intense signals in a subpopulation
of uterine cells throughout the stroma (Fig. 4A), suggesting
that truncation at the extracellular region is involved in
this expression. In contrast, all three erbB4 clones exhibited
similar cell-specific expression in the brain cortex, albeit
with modest differences in intensity. Collectively, the
uterine expression pattern of erbB4 is unique among the
erbB gene family members in that it is expressed in cells
distant from the implanting embryo. Uterine ErbB3 and
ErbB4 responded to different EGF-like ligands and exhibited
autophosphorylation, suggesting that they are biologically
active in the uterus (Fig. 5). Both erbB3 and erbB4 genes are
also expressed in day 8 embryos. This early embryonic
expression suggests their involvement in cardiac and ner-
vous system development, because midgestational abnor-
malities of these organs are manifested in mice mutated for
these genes (Gassman et al., 1995; Riethmacher et al., 1997;
Erickson et al., 1997).
The process of implantation involves dynamic cellular
changes. The epithelial cell differentiation and stromal cell
proliferation on day 4 of pregnancy (day of implantation)
prepare the uterus to the receptive state for implantation
(Dey, 1996). The earliest known molecular interaction
between the trophectoderm and luminal epithelium is the
induction of HB-EGF in the luminal epithelium exclusively
at the sites of blastocyst apposition prior to the attachment
reaction (1600 h) on day 4 (Das et al., 1994b). This epithelial
HB-EGF appears to interact with blastocyst ErbB1 in a
paracrine/juxtacrine manner (Das et al., 1994b; Raab et al.,
1996) and is followed by similar inductions of Ar, betacel-
lulin, epiregulin, and NRG1 (reviewed in Das et al., 1997)
during the attachment reaction (2300 h). The expression of
these ligands persists through early stages of implantation
on day 5. Induction of these ligands requires the presence of
active blastocysts, though the mechanism of induction is
unclear (reviewed in Das et al., 1997). The spatiotemporal
analysis of the EGF family and their receptor subtypes has
allowed us to describe potential ligand–receptor networking
during implantation. As reported previously (Das et al.,
1994a; Tong et al., 1996) and as shown in Fig. 6A, the
full-length ErbB1 is expressed in the stroma surrounding
the implanting blastocyst on day 5. In contrast, ErbB2 and
ErbB3 are predominantly expressed in the epithelium
throughout the uterus, albeit ErbB2 is expressed at basal
levels throughout the stroma. ErbB4 is expressed primarily
at the submyometrial stroma and myometrial connective
tissues with basal levels of expression throughout the
stroma. Distinct expression patterns of these receptor sub-
types suggest possible dimerization schemes (Fig. 6B). Be-
cause ErbB2 is the most favored partner for other ErbBs
(Karunagaran et al., 1996; Graus-Porta et al., 1997), the
ErbB2/ErbB3 heterodimer could be functional in the epithe-
lium upon ligand activation, while the ErbB1/ErbB2 and
ErbB2/ErbB4 heterodimer could be operative in the subepi-
thelial stroma and submyometrial stroma, respectively.
However, the formation of the ErbB1/ErbB1 or ErbB4/ErbB4
homodimer is also possible in these regions. Figure 6B also
depicts possible cellular sources of EGF-like ligands and
their sites of action. As mentioned above, Ar, HB-EGF,
epiregulin, betacellulin, and NRG1 are expressed in the
luminal epithelium and/or stroma at the sites of blastocyst
attachment. In contrast, while EGF is not expressed in the
peri-implantation uterus, TGF-a is expressed in major uter-
ine cell types regardless of the blastocyst location (reviewed
in Das et al., 1997). Thus, for the formation of the ErbB1/
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FIG. 6. A model for the ligand–receptor signaling network with the EGF family of growth factors in the uterus during implantation. (A)
Expression of the erbB gene family at the sites of implantation on day 5 is shown in darkfield photomicrographs at 403. a, erbB1 (3-day exposure);
b, erbB2 (3-day exposure); c, erbB3E (7-day exposure); d, erbB4E (12-day exposure). le, luminal epithelium; ge, glandular epithelium; s, stroma;
myo, myometrium; bl, blastocyst. (B) A schematic diagram depicting the potential ligand–receptor signaling network with the EGF family of
growth factors in the uterus during implantation is shown. This scheme is based on the mapping of the ligands and receptors in the uterus at the
sites of blastocyst implantation on day 5 of pregnancy. The scheme primarily focuses on the uterine aspects of the signaling network that is
considered important for uterine preparation for implantation. However, our preliminary results suggest that the signaling between the blastocyst
ErbBs and uterine ligands is also important for implantation, but is not within the scope of the study.
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ErbB2 heterodimer, Ar, HB-EGF, and epiregulin are avail-
able to function as autocrine/paracrine/juxtacrine factors
for stromal cell proliferation and/or differentiation. Al-
though ErbB4 is primarily localized at the submyometrial
region of the stroma, no known ErbB4 ligands such as
HB-EGF, betacellulin, and epiregulin are expressed at its
close proximity during implantation. Nonetheless, it is
possible that these ligands are secreted in the stroma and
affect ErbB4 as paracrine factors. Alternatively, novel li-
gands may exist for this receptor in the uterus.
As described above, preferential ErbB2/ErbB3 dimer for-
mation is likely to occur in the epithelium because of their
FIG. 6—Continued
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predominant coexpression in these cells. This dimerization
serves as a high-affinity receptor for NRG1 (Sliwkowski et
al., 1994) and also creates recently identified potential
binding sites for EGF and betacellulin (Alimandi et al.,
1997; Pinkas-Kramarski et al., 1998). An intriguing possi-
bility is that betacellulin utilizes the ErbB2/ErbB3 dimer in
mediating its signaling in the epithelium for implantation.
Therefore, colocalization of ErbB2 and ErbB3 suggests that
dimerization of these subtypes can directly transduce sig-
nals for epithelial cell proliferation and/or differentiation in
the peri-implantation uterus in the absence of ErbB1 (the
classic receptor for EGF and betacellulin). To test further
this possibility, coimmunoprecipitation of ErbB2 and ErbB3
upon betacellulin challenge could be studied using uterine
membrane preparations. However, difficulties are antici-
pated because these uterine receptors are expressed at
relatively low levels compared with those of overexpressor
cell lines. As mentioned above, another possible ligand for
this dimer is NRG1 which is expressed only in the stroma
at the sites of blastocyst attachment (Reese et al., 1998).
Thus, stromal NRG1 is likely to act on epithelial ErbB2/
ErbB3 in a paracrine manner. This notion is consistent with
the previous observation that NRG1 is a mesenchymal
factor which interacts with the receptors of neighboring
epithelial cells in a paracrine manner during mouse devel-
opment (Meyer and Birchmeier, 1994; Lemke, 1996).
Our mapping of the EGF-like growth factors and their
receptor subtypes in the peri-implantation mouse uterus is
the first to provide the potential site-specific networking of
these growth factors in the uterus during implantation
which could also be important and applicable to other organ
systems.
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